Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Antimicrobials, vaccines, anti-inflammatories linked to reduced risk for Alzheimer disease and dementia; antipsychotics and diabetes drugs tied to higher risk ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...